Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Syneos Health, Inc. | d235254dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 8, 2017
INC RESEARCH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 001-36730 | 27-3403111 | |
| (Commission File Number) | (IRS Employer Identification No.) |
3201 Beechleaf Court, Suite 600, Raleigh, North Carolina 27604-1547
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (919) 876-9300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| (d) | Election of Eric Paul Pâques as Director |
On February 8, 2017, the Board of Directors of the Company (the “Board”) appointed Eric Paul Pâques as a Class I director, effective immediately, to hold office until the Company’s 2018 Annual Meeting of Stockholders or until his successor is duly elected and qualified.
The Nominating and Corporate Governance Committee of the Board conducted the search for director candidates. It has not formulated any specific minimum qualifications for director candidates, but has determined certain desirable characteristics including independence, sound judgment, business specialization, technical skills, diversity and other desired qualities. After reviewing several director candidates, the Nominating and Corporate Governance Committee recommended Mr. Pâques for appointment to the Board.
There are no related party transactions between Mr. Pâques and the Company, and the Company believes that Mr. Pâques satisfies the independence requirements of Rule 5605(a)(2) of the NASDAQ Stock Market listing rules and Rule 10A-3 under the Securities Exchange Act.
Upon his appointment to the Board, the Company granted Mr. Pâques restricted stock units for 543 shares of the Company’s Class A common stock vesting in full on the one-year anniversary of the date of grant. In addition, as a member of the Board, Mr. Pâques will receive the same compensation paid by the Company to its other non-employee directors under the Company’s existing director compensation program.
A copy of the press release regarding the appointment of Mr. Pâques to the Board is attached hereto as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Press release dated February 8, 2017. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INC RESEARCH HOLDINGS, INC. | ||||||||||
| Date: February 8, 2017 | /s/ Christopher L. Gaenzle | |||||||||
| Name: | Christopher L. Gaenzle | |||||||||
| Title: | Chief Administrative Officer & General Counsel | |||||||||